FY2025 Earnings Forecast for Cassava Sciences, Inc. Issued By HC Wainwright (NASDAQ:SAVA)

Cassava Sciences, Inc. (NASDAQ:SAVA) – Research analysts at HC Wainwright issued their FY2025 EPS estimates for shares of Cassava Sciences in a research note issued on Tuesday, October 8th. HC Wainwright analyst V. Bernardino anticipates that the company will post earnings per share of ($1.75) for the year. HC Wainwright currently has a “Buy” rating and a $116.00 target price on the stock. The consensus estimate for Cassava Sciences’ current full-year earnings is ($5.70) per share.

Cassava Sciences (NASDAQ:SAVA) last posted its quarterly earnings results on Thursday, August 8th. The company reported $0.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.57. During the same quarter in the prior year, the company earned ($0.63) earnings per share.

Separately, Rodman & Renshaw restated a “buy” rating and set a $107.00 price objective on shares of Cassava Sciences in a research report on Thursday, August 8th.

Cassava Sciences Trading Down 0.6 %

Cassava Sciences stock opened at $24.86 on Thursday. The stock has a market cap of $1.19 billion, a price-to-earnings ratio of -11.47 and a beta of -0.63. The company’s 50-day moving average price is $28.19 and its two-hundred day moving average price is $22.15. Cassava Sciences has a 52 week low of $8.79 and a 52 week high of $42.20.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SAVA. State Board of Administration of Florida Retirement System grew its position in Cassava Sciences by 5.7% in the first quarter. State Board of Administration of Florida Retirement System now owns 12,149 shares of the company’s stock worth $247,000 after acquiring an additional 650 shares in the last quarter. Commonwealth Equity Services LLC grew its position in Cassava Sciences by 6.9% in the first quarter. Commonwealth Equity Services LLC now owns 45,067 shares of the company’s stock worth $914,000 after acquiring an additional 2,921 shares in the last quarter. Cable Car Capital LLC bought a new stake in Cassava Sciences in the fourth quarter worth approximately $1,204,000. NBC Securities Inc. grew its position in Cassava Sciences by 9.3% in the first quarter. NBC Securities Inc. now owns 7,650 shares of the company’s stock worth $155,000 after acquiring an additional 650 shares in the last quarter. Finally, CANADA LIFE ASSURANCE Co grew its position in Cassava Sciences by 146.7% in the first quarter. CANADA LIFE ASSURANCE Co now owns 9,408 shares of the company’s stock worth $191,000 after acquiring an additional 5,594 shares in the last quarter. 38.05% of the stock is owned by hedge funds and other institutional investors.

About Cassava Sciences

Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.